Bradykinin stimulates cell proliferation through an extracellular-regulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture

Journal of Endocrinology

Volumn 186, Issue 2, 2005, Pages 291-301

  Greco, S ^a   Elia, M G ^a   Muscella, A ^a   Romano, S ^a   Storelli, C ^a   Marsigliante, Santo ^a  

^a UNIVERSITY OF SALENTO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; BRADYKININ; CALCIUM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHOLIPASE C INHIBITOR; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; MITOGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANALYSIS OF VARIANCE; BRADYKININ; BREAST NEOPLASMS; CALCIUM; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOBLOTTING; INTRACELLULAR FLUID; MITOGEN-ACTIVATED PROTEIN KINASES; MITOGENS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, BRADYKININ; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 23844522217     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06052     Document Type: Article

References (54)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT & Saltiel AR 1995 PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. Journal of Biological Chemistry 270 27489-27494.
2. 2+ signalling in rat cortical collecting duct. Cell Calcium 22 269-275.
3. Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G & Page DL 1991 Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. PNAS 88 10435-10439.
4. Biscardi JS, Ishizawar RC, Silva CM & Parsons SJ 2000 Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Research 2 203-210.
5. Blackburn AC & Jerry DJ 2002 Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer? Breast Cancer Research 4 101-111.
6. Callans LS, Naama H, Khandelwal M, Plotkin R & Jardines L 1995 Raf-1 protein expression in human breast cancer cells. Annals of Surgical Oncology 2 38-42.
7. Chen YP, Chao J & Chao L 1988 Molecular cloning and characterisation of two rat renal kallikrein genes. Biochemistry 27 7189-7196.
8. Clements JA 1997 The molecular biology of the kallikreins and their roles in inflammation. In The Kinin System, pp 71-97. Ed. SG Farmer. London: Academic Press.
9. Clements J & Mukhtar A 1977 Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers. Immunopharmacology 36 217-220.
10. Curran T & Morgan JI 1987 Memories of fos. Bioessays 7 255-258.
11. el-Dahr SS, Figueroa CD, Gonzalez CB & Muller-Esterl W 1997 Ontogeny of bradykinin B2 receptors in the rat kidney: implications for segmental nephron maturation. Kidney International 51 739-749.
12. Descamps S, Lebourhis X, Delehedde M, Boilly B & Hondermarck H 1998 Nerve growth factor is mitogenic for tumoural but not for normal human epithelial cells. Journal of Biological Chemistry 273 16659-16662.
13. Dlamini Z, Raidoo D & Bhoola K 1999 Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma. Immunopharmacology 43 303-310.
14. Drube S & Liebmann C 2000 In varoius tumour cell lines the peptide bradykinin B2 receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist. British Journal of Pharmacology 131 1553-1560.
15. Dupont J & Le Roith D 2001 Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Molecular Pathology 54 149-154.
16. 2+ increase stimulated by pyrophosphonucelotides and bradykinin in mammary tumour cells. Cell Biochemistry and Function 13 279-286.
17. Ethier SP 1995 Growth factor synthesis and human breast cancer progression. Journal of the National Cancer Institute 87 964-973.
18. Greco S, Elia MG, Muscella A, Storelli C & Marsigliante S 2002a AT1 Angiotensin II receptor mediates intracellular calcium mobilization in normal and tumoural breast cells in primary culture. Cell Calcium 32 1-10.
19. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C & Marsigliante S 2002b Activation of angiotensin II type I receptor promotes protein kinase C translocation and cell proliferation in human cultured breast epithelial cells. Journal of Endocrinology 174 205-214.
20. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, Manca C & Marsigliante S 2003 Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. Journal of Cellular Physiology 196 370-377.
21. Greco S, Muscella A, Elia MG, Romano S, Storelli C & Marsigliante S 2004 Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. Journal of Cell Physiology 201 84-96.
22. 2+ indicators with greatly improved fluorescence properties. Journal of Biological Chemistry 260 3440-3450.
23. Harris RE, Namboodiri KK & Wynder EL 1992 Breast cancer risk: effects of estrogen replacement therapy and body mass. Journal of the National Cancer Institute 84 1575-1582.
24. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E & McTiernan A 2003 Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Research 63 6096-6101.
25. Henderson IC 1993 Risk factors for breast cancer development. Cancer 71 2127-2140.
26. Henson DE & Tarone RE 1994 Involution and the etiology of breast cancer. Cancer 74 424-429.
27. Hermann A, Buchinger P & Rehbock J 1995 Visualization of tissue kallikrein in human breast carcinoma by two-dimensional Western blotting and immunohistochemistry. Biological Chemistry Hoppe-Seyler 376 365-370.
28. Janes PW, Daly BJ, deFazio A & Sutherland RL 1994 Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9 3601-3608.
29. Jones TH, Figueroa CD, Smith C, Cullen DR & Bhoola KD 1992 Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone secreting adenomas. Journal of Endocrinology 134 149-154.
30. Koshikawa N, Yasumitsu H, Umeda M & Miyazaki K 1992 Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Research 52 5046-5053.
31. Luo SF, Wang CC, Chiu CT, Chien CS, Hsiao LD, Lin CH & Yang CM 2000 Lipopolysaccharide enhances bradykinin-induced signal transduction via activation of Ras/Raf/MEK/MAPK in canine tracheal smooth muscle cells. British Journal of Pharmacology 130 1799-1808.
32. Ma JX, Wang DZ, Ward DC, Chen L, Dessai T, Chao J & Chao L 1994 Structure and chromosomal localisation of gene (BDKRB2) encoding the bradykinin B2 receptor. Genomics 23 362-369.
33. Maeda H, Wu J, Okamoto T, Maruo K & Akaike T 1999 Kallikrein kinin in infection and cancer. Immunopharmacology 43 115-128.
34. Marceau F 1995 Kinin B1 receptors: a review. Immunopharmacology 30 1-26.
35. Michie C, Lockie F & Lynn W 2003 The challenge of mastitis. Archives of Diseases in Childhood 88 818-821.
36. +-ATPase activity. In Methods in Enzymology 156 116-119.
37. Nurcombe V, Smart CE, Chipperfield H, Cool SM, Boilly B & Hondermarck H 2000 The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. Journal of Biological Chemistry 275 30009-30018.
38. Pesquero JB & Bader M 1998 Molecular biology of the kallikrein-kinin system: from structure to function. Brazilian Journal of Medical and Biological Research 31 1197-1203.
39. Plendl J, Snyman C, Naidoo S, Sawant S, Mahabeer R & Bhoola KD 2000 Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biological Chemistry 38 1103-1115.
40. Portier CJ 2002 Endocrine dismodulation and cancer. Neuroendocrinology Letters 2 43-47.
41. Randolph JB & Waggoner AS 1997 Stability, specificity and fluorescence brightness of multiply-labeled fluorescent DNA probes. Nucleic Acid Research 25 2923-2929.
42. Ransone LJ & Verma IM 1990 Nuclear proto-oncogenes fos and jun. Annual Review of Cell Biology 6 539-557.
43. Regoli D & Barabé J 1980 Pharmacology of bradykinin and related peptides. Pharmacological Reviews 32 1-46.
44. Rehbock J, Buchinger P, Hermann A & Figueroa C 1995 Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas. Journal of Cancer Research and Clinical Oncology 121 64-68.
45. Robert RM & Gulick WJ 1989 Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis by expression of mutant ras oncogene. Journal of Cell Science 94 527-535.
46. Sachdev D & Yee D 2001 The IGF system and breast cancer. Endocrine-Related Cancer 8 197-209.
47. Stewart JM 2003 Bradykinin antagonists as anti-cancer agents. Current Pharmaceutical Design 9 2036-2042.
48. Vavrek R & Stewart JM 1985 Competitive antagonists of bradykinin. Peptides 6 161-164.
49. Velarde V, Ullian ME, Morinelli TA, Mayfield RK & Jaffa AA 1999 Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. American Journal of Physiology - Cell Physiology 277 C253-C261.
50. Venkitaraman AR 2002 Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 171-182.
51. Wakefield LM, Piek E & Bottinger EP 2001 TGF-beta signaling in mammary gland development and tumorigenesis. Journal of Mammary Gland Biology and Neoplasia 6 67-82.
52. Wiernas TK, Davis TL, Griffin BW & Sharif NA 1998 Effects of bradykinin on signal transduction, cell proliferation, and cytokine, prostaglandin E2 and collagenase-1 release from human corneal epithelial cells. British Journal of Pharmacology 123 1127-1137.
53. Xing C & Imagawa W 1999 Altered MAP kinase (ERK1,2) regulation in primary cultures of mammary tumor cells: elevated basal activity and sustained response to EGF. Carcinogenesis 20 1201-1208.
54. Yu H, Bowden DW, Spray BJ, Rich SS & Freedman BI 1998 Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease. Hypertension 31 906-911.